CAS: 6633-61-0; Methyl 2-Aminothiazole-5-Carboxylate

该化合物是一种有机化合物,其特征为硫化物环结构,即五人组成的含有硫磺和氮原子的热循环环,该化合物的特点是一个箱状酸功能组和一个氨基组,其潜力是有机合成的多功能构件.甲基酯表显示,这种箱状酸已经用甲醇消毒,其有机溶剂溶液的溶性得到加强,使其在各种化学反应中更具反应性.氨基酸和箱状酸的功能表明,它可能参与各种生物化学过程,有可能作为制药或农用化学的前体.此外,人们经常注意到,由于它们的生物活动,包括抗微生物和抗硫合物特性,含有硫酸化合物.

英文名称Methyl 2-Aminothiazole-5-Carboxylate
中文名称2-氨基噻唑-5-甲酸甲酯
IUPAC名称methyl 2-aminothiazole-5-carboxylate
其它别名2-氨基-1,3-噻唑-5-羧酸甲酯; Methyl-2-Amino-1,3-Thiazol-5-Carboxylat
CAS编号6633-61-0
MFCD编号:MFCD03788562
EINECS号:640-111-7
分子式:C5H6N2O2S
分子量:158.18
产品CID: 1644570
产品分类有机原料→分子砌块→芳杂环类化合物→噻唑类化合物

相似结构搜索
InChIKey: UJNNCGWBDJHCEM-UHFFFAOYSA-N
InChI=1S/C5H6N2O2S/c1-9-4(8)3-2-7-5(6)10-3/h2H,1H3,(H2,6,7)…
计算化学: 氢键受体数5.0氢键供体数1.0可旋转键数1.0

MSDS等安全信息

GHS象形图
GHS符号GHS07;
注释: Exclamation mark
危险类别急性毒性类别4(吸入)
急性毒性类别4(经皮)
急性毒性类别4(经口)
特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼刺激类别2
严重眼刺激类别2A
警示词Warning(警告)
危险描述H332 |吸入有害.
H312 |皮肤接触有害.
H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
风险等级Harmful
安全声明26-36/37/39
危险类别码36/37/38

欧盟法规

ECHA物质C&L通报

上下游产品

methyl 2-chloro-3-oxopropionate thiourea Methyl formate methyl chloroacetate2-aminothiazole-5-carboxamide 2-aminothiazole-5-carboxylic acid 2-chlorothiazole-5-carboxylic acid methyl ester methyl thiazole-5-carboxylate

合成工艺路线路线简述

合成目标产物 Methyl 2-Aminothiazole-5-Carboxylate 主要起始原料 Methylmalonylchloride And Carbamimidothioic Acid
(文献来源)合成步骤主要原料 Methylmalonylchloride 和 Carbamimidothioic Acid

甲酸甲酯,氯乙酸甲酯置于盐酸,Sodium Methylate体系中,用水,硫脲,甲苯作为反应溶剂,化学反应生成 2-氨基噻唑-5-甲酸甲酯
参考文献:.Alpha.-And .Beta.-Amino Acid Hydroxyethylamino Sulfonamides Useful As
标题:.Alpha.-And .Beta.-Amino Acid Hydroxyethylamino Sulfonamides Useful As
摘要:.Alpha.-和.Beta.-氨基酸羟乙基氨基磺酰胺化合物作为逆转录病毒蛋白酶抑制剂具有有效性,特别是作为hiv蛋白酶的抑制剂.

海关参考信息

2912110000-甲醛
2915110000-甲酸
2909199090-其他醚及其衍生物
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-9115124-B1
优先权日:2014-03-11
标题 :Process and intermediates for the preparation of dasatinib
发明人：BARUTO ALESSANDRO; GABOARDI MAURO; CASTALDI MARTA; CASTALDI GRAZIANO
权利人:CERBIOS PHARMA SA
摘要:The present invention relates to a process for the synthesis of dasatinib and to intermediates useful for its preparation.

专利号:US-9108954-B2
优先权日:2010-02-02
标题:Synthesis process of dasatinib and intermediate thereof
发明人：YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG
权利人:YAN RONG; YANG HAO; HOU WEN; XU YONGXIANG; NAN JING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD
摘要:Synthesis process of dasatinib is disclosed, which includes the step of reacting the compound of formula I with that of formula II to obtain the compound of formula III. Also disclosed is the compound of formula III which is used as an intermediate for synthesizing dasatinib. The substituents of R1, R2, R3 or R4 in formulae I, II or III are defined as in the description.

专利号:WO-2020223551-A1
优先权日:2019-04-30
标题 :Inhibiting otub1
发明人：MARCIN Lawrence; KAYSER-BRICKER KATHERINE
权利人:INTEGRAL EARLY DISCOVERY INC; INTEGRAL HEALTH HOLDINGS LLC
摘要:The present disclosure is directed to compounds of formulas (I) - (VII), which are useful as modulators of OTUB1. The compounds are further useful in the inhibition of OTUB1 and the treatment of diseases or disorders associated with the inhibition of OTUB1. For instance, the disclosure is concerned with compounds and compositions for inhibition of OTUB1, methods of treating diseases associated with the inhibition of OTUB1 (e.g., inflammatory diseases like irritable bowel disease and Lupus), and methods of synthesis of these compounds.

专利号:US-2013030177-A1
优先权日:2010-02-02
标题:Synthesis process of dasatinib and intermediate thereof

专利号:EP-2532662-A1
优先权日:2010-02-02
标题 :Synthesis process of dasatinib and intermediate thereof

专利号:EP-2532662-B1
优先权日:2010-02-02
标题 :Synthesis process of dasatinib and intermediate thereof